search
Back to results

Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease

Primary Purpose

Type 2 Diabetes Mellitus, Coronary Artery Disease

Status
Unknown status
Phase
Phase 4
Locations
Taiwan
Study Type
Interventional
Intervention
Ginkgo Biloba Extract (GBE)
Sponsored by
Taipei Veterans General Hospital, Taiwan
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Endothelial progenitor cell, endothelial function(FMD), Gingko Biloba Extract, Type 2 Diabetes mellitus, Stable coronary artery disease, Endothelial progenitor cells Numbers

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Thirty type 2 diabetes mellitus with stable coronary disease
  • Aged 18-80 year-old

Exclusion Criteria:

  • Previous underwent coronary artery bypass surgery or percutaneous angioplasty
  • Under insulin injection patients
  • Renal or hepatic function impairment
  • Pregnant women
  • Poor BP control(BP>175/105 mmHg)

Sites / Locations

  • Taipei Veterans General Hospital

Outcomes

Primary Outcome Measures

Number of endothelial progenitor cells, endothelial function(FMD)

Secondary Outcome Measures

Full Information

First Posted
December 20, 2009
Last Updated
December 22, 2009
Sponsor
Taipei Veterans General Hospital, Taiwan
search

1. Study Identification

Unique Protocol Identification Number
NCT01038050
Brief Title
Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease
Study Type
Interventional

2. Study Status

Record Verification Date
December 2009
Overall Recruitment Status
Unknown status
Study Start Date
October 2009 (undefined)
Primary Completion Date
November 2010 (Anticipated)
Study Completion Date
December 2010 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Taipei Veterans General Hospital, Taiwan

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Type 2 diabetes is associated with a markedly increased risk for atherosclerotic coronary arteries and cerebrovascular diseases. The major cause of death in diabetic patients is cardiovascular disease in the world including Taiwan. Atherosclerosis is a progressive disease characterized by the response of the vessel wall to chronic, multifactorial injury, which leads ultimately to the formation of atheromatous or fibrous plaques. Endothelial dysfunction is thought to be the initial stage of atherosclerosis. Endothelial dysfunction leads to impaired control of vascular tone, a decreased in the release of anti-inflammatory factors and reduced availability of nitric oxide. Endothelial dysfunction portends diabetic vasculopathy. The loss of intact endothelial integrity and function sets in motion a cascade of serial events that lead to atherosclerosis and cardiovascular complications. The standard extracts of G. biloba leaves [G. biloba extract (GBE)] are now demonstrated the cardiovascular, cerebrovascular and neuroprotective effects. The mixture of biologically active ingredients in GBE accounts for the pleiotropic effects, including antioxidant effects, inhibition of platelet aggregation and thromboxane B2 production, vasodilation and modulation of cholesterol metabolism. Clinically, GBE was widely used in management of vertigo、dementia and improving peripheral circulation. In our previous study, ginkgo biloba extract inhibits tumor necrosis factor-alpha-induced reactive oxygen species generation, transcription factor activation, and cell adhesion molecule expression in human aortic endothelial cells. In addition, the similar benefit of prevention atherosclerosis was also found in animal study. Heme oxygenase-1 (HO-1) is a factor associated with higher risk of developing some vascular disease and also a rate-limiting enzyme in heme degradation, leading to the generation of free iron, biliverdin, and carbon monoxide (CO). CO exerts potent antiproliferative and anti-inflammatory effects in the vascular walls, thereby influencing neointimal formation after vascular injury. In addition, biliverdin is subsequently metabolized to bilirubin by the enzyme biliverdin reductase. Therefore, induction of HO-1 elicits potent anti-inflammatory, antiproliferative, antithrombotic, and antioxidant effects in the circulation via the generation of CO and bilirubin. Interestingly, recent study found that a long guanidine thymidine dinucleotide repeat [(GT) n≧ 30] in the HO-1 promotor, which is linked to impaired inducibility, is associated with a higher frequency of vascular access failure. In the present study, we will investigate the effect of GBE on recovering endothelial dysfunction and inflammation in diabetic patients with stable coronary artery disease. In particularly, we intend to determine whether the GBE modulates the HO-1 expression and investigate whose genotyping including some candidate gene about atherosclerosis and hypertension will have most therapeutic effect of GBE.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus, Coronary Artery Disease
Keywords
Endothelial progenitor cell, endothelial function(FMD), Gingko Biloba Extract, Type 2 Diabetes mellitus, Stable coronary artery disease, Endothelial progenitor cells Numbers

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Ginkgo Biloba Extract (GBE)
Other Intervention Name(s)
Cerenin(Ginkgo Biloba Extract) film-coated 40 mg
Intervention Description
Ginkgo Biloba Extract 40 mg 1# tid per day for 3 months(90 days)
Primary Outcome Measure Information:
Title
Number of endothelial progenitor cells, endothelial function(FMD)
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Thirty type 2 diabetes mellitus with stable coronary disease Aged 18-80 year-old Exclusion Criteria: Previous underwent coronary artery bypass surgery or percutaneous angioplasty Under insulin injection patients Renal or hepatic function impairment Pregnant women Poor BP control(BP>175/105 mmHg)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jaw-Wen Chen, MD
Organizational Affiliation
Division of Cardiology, Taipei Veterans General Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Chin-Chou Huang, MD
Organizational Affiliation
Division of Cardiology, Taipei Veterans General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Taipei Veterans General Hospital
City
Taipei
ZIP/Postal Code
11217
Country
Taiwan

12. IPD Sharing Statement

Learn more about this trial

Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease

We'll reach out to this number within 24 hrs